Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers

An effective post-exposure prophylaxis (PEP) strategy may limit the spread of infection. However, there is no consensus regarding PEP for Middle East respiratory syndrome coronavirus (MERS-CoV) infection. This study assessed the efficacy of ribavirin and lopinavir/ritonavir as PEP for healthcare wor...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, S.Y., Lee, J.S., Son, J.S., Ko, J.H., Peck, K.R., Jung, Y., Woo, H.J., Joo, Y.S., Eom, J.S., Shi, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Healthcare Infection Society. Published by Elsevier Ltd. 2019
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114948/
https://www.ncbi.nlm.nih.gov/pubmed/30240813
http://dx.doi.org/10.1016/j.jhin.2018.09.005
Descripción
Sumario:An effective post-exposure prophylaxis (PEP) strategy may limit the spread of infection. However, there is no consensus regarding PEP for Middle East respiratory syndrome coronavirus (MERS-CoV) infection. This study assessed the efficacy of ribavirin and lopinavir/ritonavir as PEP for healthcare workers (HCWs) exposed to patients with severe MERS-CoV pre-isolation pneumonia. The safety of the PEP regimen was assessed. HCWs with high-risk exposure to MERS-CoV pre-isolation pneumonia were retrospectively enrolled. HCWs who received PEP therapy were classified into the PEP group. PEP therapy was associated with a 40% decrease in the risk of infection. There were no severe adverse events during PEP therapy.

Ejemplares similares